Difelikefalin Impurity 19 is a difelikefalin-related peptide used to profile side products and decomposition pathways. Its sequence deviates subtly from the main active backbone, altering polarity and conformational preferences. Researchers use it to challenge analytical resolution and structural-assignment robustness. Applications include stability-indicating method development, impurity mapping, and structure-property investigation.
CAT No: Z10-101-200
Synonyms/Alias:1-(L-leucyl-L-lysyl)-4-aminopiperidine-4-carboxylic acid
Difelikefalin Impurity 19 is a specialized carbohydrate compound that serves as a critical reference material in pharmaceutical research and development. As a structurally related entity to the therapeutic peptide difelikefalin, this impurity is meticulously characterized to ensure its suitability for advanced analytical applications. Researchers value its defined molecular structure, which supports the accurate identification and quantification of related substances during the drug development process. The availability of such impurities is essential for comprehensive impurity profiling, facilitating robust quality control and fostering confidence in the safety and efficacy of peptide-based therapeutics.
Pharmaceutical Impurity Profiling: Difelikefalin Impurity 19 plays a pivotal role in the precise impurity profiling of difelikefalin formulations. By serving as an authentic reference standard, it enables analytical chemists to detect, identify, and quantify trace levels of related substances within complex pharmaceutical matrices. The use of this impurity in high-performance liquid chromatography (HPLC) or mass spectrometry assays allows for the establishment of accurate retention times and fragmentation patterns, which are essential for distinguishing the parent compound from structurally similar by-products. This process is instrumental in meeting stringent quality requirements and ensuring the consistency of peptide medications throughout their lifecycle.
Analytical Method Development: The presence of Difelikefalin Impurity 19 significantly enhances the development and validation of sensitive analytical methods. Researchers utilize this impurity to challenge and optimize separation techniques, ensuring that analytical methods are capable of resolving closely related species. Its inclusion in method validation studies helps establish crucial parameters such as specificity, linearity, and detection limits. By simulating real-world sample complexity, it aids in the creation of robust protocols that maintain accuracy and precision in routine quality assessments of difelikefalin and its analogues.
Stability Studies: In stability-indicating assays, Difelikefalin Impurity 19 is indispensable for assessing the degradation pathways and shelf-life of difelikefalin drug products. Researchers incorporate this impurity into forced degradation studies to monitor potential transformation products under various environmental stress conditions. The ability to track the formation and evolution of such impurities provides valuable insights into the chemical stability of the active pharmaceutical ingredient, guiding the optimization of formulation strategies and storage conditions to maximize drug integrity over time.
Structural Elucidation and Characterization: Scientists often employ Difelikefalin Impurity 19 to facilitate the structural elucidation of unknown peaks encountered during routine analysis. Its well-defined molecular profile serves as a benchmark for interpreting complex spectroscopic data, such as nuclear magnetic resonance (NMR) or tandem mass spectrometry (MS/MS) spectra. By comparing spectral features and fragmentation patterns, researchers can confidently assign identities to minor components, streamlining the impurity identification process and supporting regulatory submissions.
Peptide Synthesis Optimization: The use of Difelikefalin Impurity 19 extends to the optimization of synthetic routes for peptide production. Synthetic chemists utilize this impurity to evaluate the efficiency of different purification strategies, monitor the effectiveness of process modifications, and minimize the generation of unwanted by-products. Insights gained from these studies contribute to the refinement of manufacturing protocols, ensuring higher yields of the desired peptide with reduced impurity content. By integrating this impurity into process development workflows, manufacturers can achieve greater control over product quality and reproducibility.
In summary, Difelikefalin Impurity 19 is an indispensable tool across multiple facets of pharmaceutical research and development. From impurity profiling and analytical method validation to stability testing, structural elucidation, and process optimization, its applications are integral to advancing the science of peptide therapeutics. Its presence in the research laboratory empowers scientists to achieve greater accuracy, reliability, and confidence in the development and quality assurance of difelikefalin-based drug products.
1. Myotropic activity of allatostatins in tenebrionid beetles
4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More